Application of the Meet-URO score to metastatic renal cell carcinoma patients treated with second- and third-line cabozantinib
![JPM | Free Full-Text | Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study | HTML JPM | Free Full-Text | Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study | HTML](https://www.mdpi.com/jpm/jpm-12-00727/article_deploy/html/images/jpm-12-00727-g001.png)
JPM | Free Full-Text | Validation of a Novel Three-Dimensional (3D Fusion) Gross Sampling Protocol for Clear Cell Renal Cell Carcinoma to Overcome Intratumoral Heterogeneity: The Meet-Uro 18 Study | HTML
![Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting | Future Oncology Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting | Future Oncology](https://www.futuremedicine.com/cms/10.2217/fon.14.48/asset/images/medium/figure3.gif)
Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting | Future Oncology
![Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting | Future Oncology Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting | Future Oncology](https://www.futuremedicine.com/cms/10.2217/fon.14.48/asset/images/medium/figure2.gif)
Sorafenib as first- or second-line therapy in patients with metastatic renal cell carcinoma in a community setting | Future Oncology
Natural History of Malignant Bone Disease in Renal Cancer: Final Results of an Italian Bone Metastasis Survey | PLOS ONE
![Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real‐world results from an expanded access programme - De Giorgi - 2019 - BJU International - Wiley Online Library Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real‐world results from an expanded access programme - De Giorgi - 2019 - BJU International - Wiley Online Library](https://bjui-journals.onlinelibrary.wiley.com/cms/asset/bb6ae09d-81ab-4595-aefd-73ea216292ad/bju.2019.123.issue-1.cover.jpg)
Safety and efficacy of nivolumab for metastatic renal cell carcinoma: real‐world results from an expanded access programme - De Giorgi - 2019 - BJU International - Wiley Online Library
![Gaetano PEZZICOLI | Medical Doctor | Doctor of Medicine | Università degli Studi di Bari Aldo Moro, Bari | Università di Bari | Dipartimento di Scienze Biomediche ed Oncologia Umana (DIMO) Gaetano PEZZICOLI | Medical Doctor | Doctor of Medicine | Università degli Studi di Bari Aldo Moro, Bari | Università di Bari | Dipartimento di Scienze Biomediche ed Oncologia Umana (DIMO)](https://i1.rgstatic.net/ii/profile.image/1069256951209984-1631942131234_Q512/Gaetano-Pezzicoli-2.jpg)
Gaetano PEZZICOLI | Medical Doctor | Doctor of Medicine | Università degli Studi di Bari Aldo Moro, Bari | Università di Bari | Dipartimento di Scienze Biomediche ed Oncologia Umana (DIMO)
![Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial - ScienceDirect Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0959804921003919-ga1.jpg)
Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial - ScienceDirect
![Daniel CASTELLANO | Hospital Universitario 12 de Octubre, Madrid | 12OCTUBRE | Medical Oncology Department Daniel CASTELLANO | Hospital Universitario 12 de Octubre, Madrid | 12OCTUBRE | Medical Oncology Department](https://i1.rgstatic.net/ii/profile.image/864677676457984-1583166631246_Q512/Daniel-Castellano.jpg)
Daniel CASTELLANO | Hospital Universitario 12 de Octubre, Madrid | 12OCTUBRE | Medical Oncology Department
![Nicola SILVESTRIS | Full professor | Professor | Università degli Studi di Messina, Messina | UNIME - Page 4 Nicola SILVESTRIS | Full professor | Professor | Università degli Studi di Messina, Messina | UNIME - Page 4](https://i1.rgstatic.net/ii/profile.image/394509356683264-1471069768460_Q512/Nicola-Silvestris.jpg)
Nicola SILVESTRIS | Full professor | Professor | Università degli Studi di Messina, Messina | UNIME - Page 4
![Alessandra Bearz's research works | CRO Centro di Riferimento Oncologico di Aviano, Aviano (CRO) and other places Alessandra Bearz's research works | CRO Centro di Riferimento Oncologico di Aviano, Aviano (CRO) and other places](https://www.researchgate.net/publication/361726398/figure/fig1/AS:1175677302775808@1657314720449/Alternative-splicing-leads-to-several-variants-of-EML4-ALK-fusion-gene_Q320.jpg)
Alessandra Bearz's research works | CRO Centro di Riferimento Oncologico di Aviano, Aviano (CRO) and other places
![Sebastiano BUTI | Medical Doctor | MD, PhD | University Hospital of Parma, Parma | AOUP | Reparto di Oncologia medica - Page 8 Sebastiano BUTI | Medical Doctor | MD, PhD | University Hospital of Parma, Parma | AOUP | Reparto di Oncologia medica - Page 8](https://i1.rgstatic.net/ii/profile.image/272303485353996-1441933618320_Q512/Sebastiano-Buti.jpg)